AllSci News
Chai’s AI miniprotein engine joins Lilly’s TuneLab ecosystem for select biotech partners
San Francisco-based Chai Discovery announced a collaboration with Eli Lilly and Company’s (NYSE: LLY) TuneLab platform that will make Chai’s frontier AI…
Merck’s Capvaxive becomes first PCV approved specifically for high-risk children aged 2-17
Merck (NYSE: MRK) has received US FDA approval for an expanded indication related to Capvaxive (pneumococcal 21-valent conjugate vaccine), extending its use…
Portal's mechanoporation platform scales to 100 pharma and academic sites with USD 9 million round
Watertown, Massachusetts-based Portal Biotechnologies, Inc., a cell engineering and drug discovery platform company, has closed an oversubscribed USD 9...
Nortiva Bio launches with USD 5m Gates Foundation grant for long-acting oral contraceptive
Lexington, Massachusetts-based Nortiva Bio, Inc. has launched as a clinical-stage biopharmaceutical company focused on extending the duration of oral...
Voro and Alloy combine tumor-targeting and T-cell engineering to curb engager toxicity
San Diego-based Voro Therapeutics and Boston-based Alloy Therapeutics have announced a strategic research collaboration to discover and develop next-generation masked T-cell engager…
Takeda deploys Boltz’s biomolecular AI across research organization in platform access deal
Massachusetts-based Boltz PBC and Takeda announced a platform collaboration under which Boltz’s proprietary biomolecular AI models will be deployed across Takeda’s Research…
Scribe takes USD 25m in CIRM funding to push CRISPR CVD programs into clinic
Scribe Therapeutics has received more than USD 25 million from the California Institute for Regenerative Medicine (CIRM) to advance two preclinical...
RedHill raises USD 19.4m to fund acquisition hunt amid cash crunch
Israel-based RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a private placement of ADSs and accompanying warrants with potential gross proceeds of up to...
Sanofi backs Cour's nanoparticle therapy for type 1 diabetes in USD 50m Series B
Skokie, Illinois-based COUR Pharma has closed a USD 50 million Series B financing round to advance CNP-103, its lead nanoparticle-based immune tolerance...
cAMPfield launches with USD 180m to challenge oral IBD therapy's tolerability barrier
San Diego-based cAMPfield Therapeutics, Inc. has launched with a USD 180 million Series A financing to advance prifemilast (HY1999/HPP737), a once-daily...
Acumen secures exclusive Alzheimer's license for JCR's brain-penetrating antibody platform
Acumen Pharmaceuticals (Nasdaq: ABOS) has exercised its exclusive option under its collaboration with Japan-based JCR Pharmaceuticals Co., Ltd. (TSE: 4552),...
Spot Biosystems emerges from stealth with USD 40 million, early human data for non-viral dystrophin delivery
Palo Alto-based Spot Biosystems has emerged from stealth with USD 40 million in venture financing and early clinical data suggesting its extracellular...
Legend Bio raises USD 226 million to fund pipeline as CARVYKTI sales accelerate toward 2026 profitability
Bridgewater, New Jersey-based Legend Biotech Corporation (Nasdaq: LEGN) announced the pricing of an underwritten public offering of American Depositary...
LG Chem bets on AI-designed antibodies to solve solid tumor toxicity problem
South Korea-based LG Chem (KRX: 051910) has agreed to fund discovery of a tumour-selective multispecific antibody through UK-based LabGenius Therapeutics,...
D&D Pharmatech pairs oral peptide platform with LG's generative AI to accelerate drug discovery
D&D Pharmatech (KOSDAQ: 347850), whose oral peptide delivery platform has attracted over USD 7 billion in downstream pharma acquisitions, has signed a...
The AllSci Brief
Systematic R&D and deal news. Daily.